Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 75 articles:
HTML format
Text format



Single Articles


    April 2019
  1. MUKHOPADHYAY UK, Oturkar CC, Adams C, Wickramasekera N, et al
    TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452444. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. BADVE S, Gokmen-Polar Y
    TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452445. doi: 10.1093.
    PubMed     Text format    


  3. XU Z, Sandler DP, Taylor JA
    Blood DNA methylation and breast cancer: A prospective case-cohort analysis in the Sister Study.
    J Natl Cancer Inst. 2019 Apr 15. pii: 5466458. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  5. KIM RS, Song N, Gavin PG, Salgado R, et al
    Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
    J Natl Cancer Inst. 2019 Mar 19. pii: 5393262. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. RODRIGUEZ-RUIZ A, Lang K, Gubern-Merida A, Broeders M, et al
    Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists.
    J Natl Cancer Inst. 2019 Mar 5. pii: 5307077. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  7. KRESOVICH JK, Xu Z, O'Brien KM, Weinberg CR, et al
    Methylation-based biological age and breast cancer risk.
    J Natl Cancer Inst. 2019 Feb 22. pii: 5341521. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. NGUYEN B, Veys I, Leduc S, Bareche Y, et al
    Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
    J Natl Cancer Inst. 2019 Feb 21. pii: 5355042. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. COHN BA, Cirillo PM, Terry MB
    DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.
    J Natl Cancer Inst. 2019 Feb 13. pii: 5299924. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. LEE CI, Elmore JG
    Artificial Intelligence for Breast Cancer Imaging: The New Frontier?
    J Natl Cancer Inst. 2019 Feb 5. pii: 5307046. doi: 10.1093.
    PubMed     Text format    


    January 2019
  11. ABDEL-QADIR H, Thavendiranathan P, Austin PC, Lee DS, et al
    The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304781. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. LENIHAN DJ
    Cardiac Disease After Breast Cancer Treatment: Make Sure to Check Our Blind Spot!
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304780. doi: 10.1093.
    PubMed     Text format    


  13. KRAMER I, Schaapveld M, Oldenburg HSA, Sonke GS, et al
    The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304371. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. CHEUNG KJ, Davidson NE
    Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303805. doi: 10.1093.
    PubMed     Text format    


  15. PAREJA F, Lee JY, Brown DN, Piscuoglio S, et al
    The Genomic Landscape of Mucinous Breast Cancer.
    J Natl Cancer Inst. 2019 Jan 11. pii: 5288408. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. REEVES KW, Santana MD, Manson JE, Hankinson SE, et al
    Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284913. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. HUILLARD O, Le Strat Y, Dubertret C, Goldwasser F, et al
    RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284914. doi: 10.1093.
    PubMed     Text format    


  18. SPRAGUE BL, Kerlikowske K, Bowles EJA, Rauscher GH, et al
    Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2019 Jan 8. pii: 5280767. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2018
  19. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5193772. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5342932. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. KENSLER KH, Poole EM, Heng YJ, Collins LC, et al
    Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    J Natl Cancer Inst. 2018 Nov 15. pii: 5184399. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. CARREIRA H, Williams R, Muller M, Harewood R, et al
    Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
    J Natl Cancer Inst. 2018 Nov 7. pii: 5164282. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  24. QIAN F, Wang S, Mitchell J, McGuffog L, et al
    Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
    J Natl Cancer Inst. 2018 Oct 12. pii: 5128773. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. TRAPP E, Janni W, Schindlbeck C, Juckstock J, et al
    Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127124. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. SPARANO JA, Henry NL
    Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127122. doi: 10.1093.
    PubMed     Text format    


  27. DESANTIS CE, Jemal A
    Re: Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Oct 10. pii: 5126439. doi: 10.1093.
    PubMed     Text format    


    September 2018
  28. LEE JY, Joo HS, Choi HJ, Jin S, et al
    Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 27. pii: 5103386. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. HELZLSOUER KJ
    Can Less Be More for Individuals With Low-Risk Breast Cancer?
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101448. doi: 10.1093.
    PubMed     Text format    


  30. JAYASEKERA J, Schechter CB, Sparano JA, Jagsi R, et al
    Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101449. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  31. MARINOVICH ML, Hunter KE, Macaskill P, Houssami N, et al
    Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall.
    J Natl Cancer Inst. 2018 Aug 9. pii: 5068658. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. SHIMELIS H, LaDuca H, Hu C, Hart SN, et al
    Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    J Natl Cancer Inst. 2018 Aug 7. pii: 5062996. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  33. DIERAS V, Rugo HS, Schnell P, Gelmon K, et al
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 18. pii: 5055701. doi: 10.1093.
    PubMed     Text format     Abstract available



  34. Corrigendum to "Cost and Complications of Local Therapies for Early-Stage Breast Cancer".
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054617. doi: 10.1093.
    PubMed     Text format    


  35. LU DL, Le Cornet C, Sookthai D, Johnson TS, et al
    Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054612. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. DAVIS LYNN BC, Rosenberg PS, Anderson WF, Gierach GL, et al
    Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Jul 5. pii: 5049141. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  37. LAMBERTINI M, Campbell C, Bines J, Korde LA, et al
    Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033460. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. CATHCART-RAKE E, Gast KC, Ruddy KJ
    What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033462. doi: 10.1093.
    PubMed     Text format    



  39. Corrigendum to "Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer".
    J Natl Cancer Inst. 2018;110:684.
    PubMed     Text format    


    May 2018
  40. PATTERSON RE, Marinac CR, Sears DD, Kerr J, et al
    The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
    J Natl Cancer Inst. 2018 May 18. pii: 4999668. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. LOHMANN AE, Pimentel I, Goodwin PJ
    Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
    J Natl Cancer Inst. 2018 May 18. pii: 4999672. doi: 10.1093.
    PubMed     Text format    


    April 2018
  42. DESMEDT C, Demicheli R, Fornili M, Bachir I, et al
    Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
    J Natl Cancer Inst. 2018 Apr 30. pii: 4975381. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. JAYASEKERA J, Li Y, Schechter CB, Jagsi R, et al
    Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990602. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  46. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    March 2018
  47. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    PubMed     Text format    


  48. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    PubMed     Text format    


  49. RITZWOLLER DP, Hassett MJ, Uno H, Cronin AM, et al
    Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
    J Natl Cancer Inst. 2018;110:273-281.
    PubMed     Text format     Abstract available


    February 2018
  50. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    PubMed     Text format    


  53. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    PubMed     Text format    


  55. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  57. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  58. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    January 2018
  59. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed     Text format    


  61. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed     Text format    


  62. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  65. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  66. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  67. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    PubMed     Text format    


  68. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  70. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed     Text format    


  71. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  72. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  73. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  74. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  75. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: